MX2020007010A - Vectores modificados de orthopoxvirus. - Google Patents

Vectores modificados de orthopoxvirus.

Info

Publication number
MX2020007010A
MX2020007010A MX2020007010A MX2020007010A MX2020007010A MX 2020007010 A MX2020007010 A MX 2020007010A MX 2020007010 A MX2020007010 A MX 2020007010A MX 2020007010 A MX2020007010 A MX 2020007010A MX 2020007010 A MX2020007010 A MX 2020007010A
Authority
MX
Mexico
Prior art keywords
modified orthopoxvirus
vectors
orthopoxvirus vectors
modified
amenable
Prior art date
Application number
MX2020007010A
Other languages
English (en)
Inventor
John C Bell
Boeuf Fabrice Le
Michael S Huh
Matthew Y Tang
Brian Andrew Keller
Adrian Pelin
Caroline J Breitbach
Michael F Burgess
Steven H Bernstein
Original Assignee
Ottawa Hospital Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Hospital Res Inst filed Critical Ottawa Hospital Res Inst
Publication of MX2020007010A publication Critical patent/MX2020007010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01023—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1) dUTP diphosphatase (3.6.1.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La descripción se refiere a vectores modificados de Orthopoxvirus, así como a métodos para usarlos para el tratamiento de varios cánceres. La descripción proporciona vectores modificados de Orthopoxvirus que exhiben varias actividades terapéuticas beneficiosas, incluidas actividad oncolítica mejorada, propagación de infección, evasión inmunitaria, persistencia del tumor, capacidad para la incorporación de secuencias de ADN exógenas y seguridad. Los virus que se han descubierto también son manejables mediante protocolos de fabricación a gran escala.
MX2020007010A 2018-01-05 2019-01-04 Vectores modificados de orthopoxvirus. MX2020007010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614349P 2018-01-05 2018-01-05
US201862784371P 2018-12-21 2018-12-21
PCT/CA2019/050014 WO2019134048A1 (en) 2018-01-05 2019-01-04 Modified orthopoxvirus vectors

Publications (1)

Publication Number Publication Date
MX2020007010A true MX2020007010A (es) 2020-12-10

Family

ID=67144045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007010A MX2020007010A (es) 2018-01-05 2019-01-04 Vectores modificados de orthopoxvirus.

Country Status (12)

Country Link
US (1) US11802292B2 (es)
EP (1) EP3735466A4 (es)
JP (2) JP7312412B2 (es)
KR (1) KR20200121297A (es)
CN (1) CN113039277A (es)
AU (1) AU2019205036A1 (es)
BR (1) BR112020013769A2 (es)
CA (1) CA3122431A1 (es)
IL (1) IL275813A (es)
MX (1) MX2020007010A (es)
SG (1) SG11202006457YA (es)
WO (1) WO2019134048A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021012078A2 (pt) * 2018-12-21 2021-08-31 Ottawa Hospital Research Institute Vetores de ortopoxvírus modificados
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
BR112021017551A2 (pt) * 2019-03-05 2021-11-09 Amgen Inc Uso de vírus oncolíticos para o tratamento de câncer
CN113840914A (zh) * 2019-05-14 2021-12-24 国立大学法人鸟取大学 诱导细胞融合的痘苗病毒及其应用
WO2023135313A1 (en) * 2022-01-17 2023-07-20 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
AU2003290528A1 (en) 2002-10-15 2004-05-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods and reagents for inducing immunity
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2009152133A1 (en) 2008-06-10 2009-12-17 Abbott Laboratories Novel tricyclic compounds
WO2015027163A1 (en) 2013-08-22 2015-02-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-oncolytic therapies
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
CN105255840A (zh) 2015-10-16 2016-01-20 西安医学院 通过去除显性表位b8r重组痘苗病毒的方法及其病毒
CA3011157A1 (en) 2016-01-11 2017-07-20 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
JP6794442B2 (ja) 2016-05-30 2020-12-02 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
RU2621868C1 (ru) 2016-06-24 2017-06-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор"" (ФБУН ГНЦ ВБ "Вектор") Рекомбинантный штамм VACΔ6 вируса осповакцины с нарушенными генами вирулентности C3L, N1L, J2R, A35R, A56R, B8R для получения живой культуральной аттенуированной вакцины против натуральной оспы и других ортопоксвирусных инфекций человека
AU2018229278A1 (en) 2017-02-28 2019-10-17 Sanofi Therapeutic RNA
CN111212914A (zh) 2017-07-14 2020-05-29 昂克诺斯公司 包封的多核苷酸和使用方法
US20210093684A1 (en) 2017-10-31 2021-04-01 KaliVir Immunotherapeutics LLC Platform oncolytic vector for systemic delivery
WO2019134049A1 (en) 2018-01-05 2019-07-11 Bell John C Modified vaccinia vectors
BR112021012078A2 (pt) 2018-12-21 2021-08-31 Ottawa Hospital Research Institute Vetores de ortopoxvírus modificados

Also Published As

Publication number Publication date
JP2023126868A (ja) 2023-09-12
CA3122431A1 (en) 2019-07-11
SG11202006457YA (en) 2020-08-28
US20200392535A1 (en) 2020-12-17
BR112020013769A2 (pt) 2020-12-01
JP7312412B2 (ja) 2023-07-21
CN113039277A (zh) 2021-06-25
EP3735466A4 (en) 2022-01-12
KR20200121297A (ko) 2020-10-23
WO2019134048A1 (en) 2019-07-11
IL275813A (en) 2020-08-31
US11802292B2 (en) 2023-10-31
JP2021510082A (ja) 2021-04-15
EP3735466A1 (en) 2020-11-11
AU2019205036A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
MX2020007011A (es) Vectores de vaccinia modificados.
MX2020007010A (es) Vectores modificados de orthopoxvirus.
PH12021551436A1 (en) Modified orthopoxvirus vectors
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
PH12019502518A1 (en) Alphavirus neoantigen vectors
CO2017009104A2 (es) Derivados dinucleotidos de purina bis-2’-fluoro-bis-3’-5’-cíclico
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
MX2018008266A (es) Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer.
EP4219696A3 (en) Oncolytic virus strain
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
AU2017234929B2 (en) Therapeutic for treatment of diseases including the central nervous system
EP4310500A3 (en) Methods and compositons for the activation of gamma-delta t-cells
MX2021014525A (es) Adenovirus modificados.
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
AU2013358947A8 (en) WT1 vaccine
PH12017501993A1 (en) Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy
WO2014026110A3 (en) Compounds for improved viral transduction
MX2018015172A (es) Metodos para tratar cancer pancreatico.
RU2015143513A (ru) Микровезикула и способ ее получения
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
WO2015170158A8 (en) Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
WO2020000035A8 (en) Modified t cells and uses thereof